

Your reference
Our reference
Date

July 18, 2025

Changes to BNP Paribas Funds (“BNP”) and the Underlying Funds (as defined below)

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

We accept full responsibility for the accuracy of the content of this document.

Dear valued customer,

We are writing to let you know about the changes to BNP and the Underlying Funds. You have invested in at least one of the investment choices corresponding to the Underlying Funds, which are listed in the “Which investment choices are affected?” table below under the column “Name and code of the investment choice”.

Which investment choices are affected?

Name and code of the investment choice (Individually, the “Investment Choice”; collectively, the “Investment Choices”)	Name of the corresponding underlying fund (Individually, the “Underlying Fund”; collectively, the “Underlying Funds”)	Applicable scheme (Collectively, the “Schemes”)
BNP Paribas Funds - Aqua (code: PNUSD)	BNP Paribas Funds - Aqua	<ul style="list-style-type: none"> • Magnitude • Matterhorn • Swiss Elite
BNP Paribas Funds - Brazil Equity (code: M5USD)	BNP Paribas Funds - Brazil Equity	
BNP Paribas Funds - China Equity (code: M6USD)	BNP Paribas Funds - China Equity	
BNP Paribas Funds - Consumer Innovators (code: POUSD)	BNP Paribas Funds - Consumer Innovators	
BNP Paribas Funds - Clean Energy Solutions (code: PPUUSD)	BNP Paribas Funds - Clean Energy Solutions	
BNP Paribas Funds - Health Care Innovators (code: SHUSD)	BNP Paribas Funds - Health Care Innovators	<ul style="list-style-type: none"> • Magnitude
BNP Paribas Funds - Russia Equity (Code: M7USD)*	BNP Paribas Funds - Russia Equity	

*This investment choice is currently suspended for new subscription, redemption and switching.

What is happening?

We have been notified by the board of directors of BNP (the “Board”) of the following changes to the Underlying Funds that will be incorporated in the next version of the Hong Kong Offering Document of BNP, and will be effective on August 1, 2025 (the “Effective Date”).

Zurich Assurance Ltd
(a company incorporated
in England and Wales
with limited liability)

**Zurich Life Insurance
(Hong Kong) Limited**
(a company incorporated in
Hong Kong with limited liability)

25-26/F, One Island East
18 Westlands Road
Island East, Hong Kong

Website: www.zurich.com.hk

Appointment of BNP PARIBAS ASSET MANAGEMENT Singapore Limited

BNP adopted a “pool approach” whereby the management company of BNP has delegated its discretionary investment management functions in respect of each of the sub-funds of BNP to one or more investment managers.

Following a review of the investment capabilities across the entities of BNP Paribas group, a BNP Paribas Group management entity, BNP PARIBAS ASSET MANAGEMENT Singapore Limited (registered and regulated by Monetary Authority of Singapore), will be appointed as a new investment manager for SFC-authorized sub-funds¹ of BNP with effect from the Effective Day.

As confirmed by the Board, the change of the investment managers of the Underlying Funds will not result in any change in fees level or costs in managing the Underlying Funds. In addition, no costs and/or expenses will be incurred in connection with the change. The change would not materially change the features and overall risk profile of the Underlying Funds. There would be no change in the operations or the manner in which the Underlying Funds are being managed. There would be no change in the investment objective or policy of the Underlying Funds as a result of the change. Further, the change would not materially prejudice the existing investors' rights of interest.

Details of the relevant portfolio manager(s) responsible for a particular Underlying Fund will be listed in the annual report of BNP. The Hong Kong offering document of BNP will be updated to reflect the change above. The current Hong Kong offering document of BNP is available on the website at <https://www.bnpparibas-am.com/en-hk>². The updated Hong Kong offering document will be available later.

What does this mean to you?

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge, except for BNP Paribas Funds - Russia Equity (Code: M7USD) which is currently suspended for new subscription, redemption and switching.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 2968 2383 or contact us via <https://www.zurich.com.hk/zh-hk/customer-services/contact-us/e-form/life-general> and we will be happy to help.

Yours faithfully,

Zurich Life Insurance (Hong Kong) Limited
(a company incorporated in Hong Kong with limited liability)

Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.

¹ SFC authorization is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

² This website has not been reviewed by the Securities and Futures Commission of Hong Kong.

有關法巴基金（「法巴」）及該等相關基金（定義見下文）之變更

此乃重要函件，務請您即時垂注。您如對本函件的内容有任何疑問，請尋求專業意見。

蘇黎世人壽
(於英格蘭及威爾斯註冊
成立之有限公司)

我們就此函件所轉載資料的準確性承擔全部責任。

親愛的客戶：

蘇黎世人壽保險（香港）有限公司
(於香港註冊成立之有限公司)

我們謹此致函通知您有關法巴及該等相關基金的變更。您已投資於該等相關基金相應的至少一個投資選擇，其列於下表「受影響的投資選擇」中「投資選擇的名稱及代碼」一欄。

香港港島東華蘭路18號
港島東中心25-26樓

受影響的投資選項

網址: www.zurich.com.hk

投資選項（各稱為「該投資選擇」，統稱為「該等投資選擇」）的名稱及代碼	相應的相關基金（各稱為「該相關基金」，統稱為「該等相關基金」）名稱	適用計劃（統稱「計劃」）
法巴基金 - 法巴水資源基金 (代碼：PNUSD)	法巴基金 - 法巴水資源基金	<ul style="list-style-type: none">瑞豐投資計劃瑞承投資計劃瑞翔投資計劃
法巴基金 - 法巴巴西股票基金 (代碼：M5USD)	法巴基金 - 法巴巴西股票基金	
法巴基金 - 法巴中國股票基金 (代碼：M6USD)	法巴基金 - 法巴中國股票基金	
法巴基金 - 法巴主要消費品創 新股票基金 (代碼：POUSD)	法巴基金 - 法巴主要消費品創 新股票基金	
法巴基金 - 法巴潔淨能源基金 (代碼：PPUSD)	法巴基金 - 法巴潔淨能源基金	
法巴基金 - 法巴健康護理創新 基金 (代碼：SHUSD)	法巴基金 - 法巴健康護理創新 基金	
法巴基金 - 法巴俄羅斯股票基 金 (代碼：M7USD) *	法巴基金 - 法巴俄羅斯股票基 金	<ul style="list-style-type: none">瑞豐投資計劃

*此投資選項目前暫停認購、贖回及轉換。

修訂事項

法巴的董事會（「該董事會」）已通知我們，以下對該等相關基金的變動將會納入法巴下一版本的香港銷售文件，並將於2025年8月1日（「生效日期」）生效。

委任 BNP PARIBAS ASSET MANAGEMENT Singapore Limited

法巴採取「匯集策略」，據此，法巴的管理公司已就每項法巴子基金轉授其全權委託投資管理職能予一名或多名投資經理。

在審視法國巴黎銀行集團各實體的投資能力後，由生效日期起，法國巴黎銀行集團管理實體 BNP PARIBAS ASSET MANAGEMENT Singapore Limited (於新加坡金融管理局註冊和受其監管) 將獲委任為法巴旗下獲證監會認可的子基金¹之新投資經理。

該董事會已確認，該等相關基金的投資經理的變動不會改變管理該等相關基金的費用水平或成本。此外，變動不會招致任何成本及 / 或開支。該項變動不會顯著改變該等相關基金的特點及整體風險範圍。該等相關基金的運作或管理方式並無改變。此外，該項變動不會導致該等相關基金的投資目標或政策出現任何變動，亦不會顯著損害現有投資者的權利或權益。

負責某一該相關基金的有關投資組合經理的詳情將列載於法巴年度報告內。法巴香港銷售文件將作出更新以反映上述變動。現有的法巴香港銷售文件載於網站 <https://www.bnpparibas-am.com/zh-hk>²。經更新的法巴香港銷售文件將於稍後提供。

對您產生的影響

如您在考慮上述變更後仍希望繼續投資於該等投資選項，則無需就此修訂作出任何行動。倘若您不欲繼續投資於該等投資選項，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選項的指示 (除了目前暫停認購、贖回及轉換的法巴基金 - 法巴俄羅斯股票基金 (代碼：M7USD))，費用全免。

我們建議您首先諮詢您的持牌保險中介人，以取得其他投資選項的建議。有關本公司投資選項 (包括費用及收費，以及其相關風險因素) 的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

如您對本函件或投資選項中的投資有任何疑問，請聯絡您的持牌保險中介人。您亦可致電+852 2968 2383或經由 <https://www.zurich.com.hk/zh-hk/customer-services/contact-us/e-form/life-general> 聯絡我們，我們將樂意為您效勞。

蘇黎世人壽保險 (香港) 有限公司
(於香港註冊成立之有限公司)
2025年7月18日

註：投資涉及風險，您的投資價值及收益可因市場及貨幣波動而下跌，有可能導致您不能取回所有投資款項。

¹ 證監會的認可並不等如對計劃作出推介或認許，亦不是對計劃的商業利弊或表現作出保證；有關認可不代表計劃適合所有投資者，或認許計劃適合任何個別投資者或任何類別的投資者。

² 此網站未經香港證券及期貨事務監察委員會審閱。